Seeking Alpha
搜索文档
KSLV: Silver Exposure With High Income And Few Compromises
Seeking Alpha· 2025-12-25 14:50
文章核心观点 - 分析师对Kurv Gold Enhanced Income ETF给予买入评级 因其策略和执行均受认可 这在收益型ETF市场中较为罕见 [1] 分析师背景与投资方法 - 分析师为宏观导向和数据驱动的投资者 专注于发现被忽视的信息关联 并通过集中、不对称和高确信度的头寸表达观点 [1] - 分析师强调风险管理与头寸规模控制 认为其重要性常超过证券选择本身 [1] - 分析师致力于在主流财经媒体之前发掘叙事趋势 将此过程称为寻找信息阿尔法 [1] 持仓披露 - 分析师通过股票、期权或其他衍生品持有GLD和GLTR的多头头寸 [1]
ICOP: Copper Great, But Iron Ore A Bit More Downside Exposed
Seeking Alpha· 2025-12-25 14:37
投资服务与策略 - 该投资服务专注于全球宏观评论与长线价值投资 旨在寻找国际市场上被错误定价的股票 其投资组合目标收益率约为4% [1] - 该团队在过去5年取得了优异的投资业绩 其经验源于深入参与国际市场 [1] - 该服务由Valkyrie Trading Society团队运营 他们分享高确信度且鲜为人知的发达市场投资观点 这些观点下行风险有限 并可能在当前经济环境下产生非相关性和超额回报 [2] - 该团队为纯多头投资者 为其会员提供实时更新的投资组合 24/7问答聊天 定期全球市场新闻报告 对会员个股想法的反馈 每月新交易 季度财报分析以及每日宏观观点 [2] 基金与公司 - iShares铜与金属矿业ETF对铜有显著风险敞口 其持仓包括Freeport-McMoRan等公司 [2] - 该ETF也持有其他矿业巨头 如Anglo American和BHP Group [2]
Nvidia: Poised To Unlock $6 Trillion In 2026
Seeking Alpha· 2025-12-25 14:35
核心观点 - 华尔街分析师认为英伟达公司股票目前被显著低估 其估值倍数在未来几年将随着公司持续将收入增长转化为盈利增长而大幅收缩 [1] 作者背景与立场 - 文章作者在四大审计事务所拥有十年从业经验 专注于银行、矿业和能源领域 具备扎实的金融和战略基础 [1] - 作者目前担任一家领先零售房地产所有者和运营商的财务主管 负责复杂的财务运营和战略 [1] - 作者拥有13年美国股市主动投资经验 投资组合采用平衡策略 在保持对增长机会敞口的同时 日益关注价值股 [1] - 作者披露其通过股票、期权或其他衍生品持有英伟达公司的多头头寸 [2]
Nvidia: Poised To Unlock $6 Trillion In 2026 (NASDAQ:NVDA)
Seeking Alpha· 2025-12-25 14:35
Wall Street analysts believe that Nvidia ( NVDA ) is significantly undervalued, and I totally agree with it. The company's valuation multiples are poised to contract dramatically over the next few years as it keeps convertingWith a decade at a Big 4 audit firm specializing in the banking, mining, and energy sectors, I bring a strong foundation in finance and strategy. Currently, I serve as the Head of Finance for a leading owner and operator of retail real estate, where I oversee complex financial operation ...
Wahed FTSE USA Shariah ETF declares quarterly distribution of $0.0772 (NASDAQ:HLAL)
Seeking Alpha· 2025-12-25 14:13
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...
Nvidia: What Should Investors Make Of The Groq Deal (Rating Upgrade)
Seeking Alpha· 2025-12-25 13:45
投资理念与策略 - 投资目标为寻找具备完美定性特征的公司 以基于基本面的有吸引力价格买入并永久持有 [1] - 投资组合高度集中 旨在规避亏损并最大化对赢家的敞口 [1] - 即使对于优秀的公司 若其增长机会低于阈值或下行风险过高 也可能仅给予“持有”评级 [1] 内容发布计划 - 计划每周发布约3篇覆盖此类公司的文章 [1] - 进行广泛的季度跟踪和持续更新 [1]
Nvidia: What Should Investors Make Of The Groq Deal (Rating Upgrade) (NASDAQ:NVDA)
Seeking Alpha· 2025-12-25 13:45
I aim to invest in companies with perfect qualitative attributes, buy them at an attractive price based on fundamentals, and hold them forever. I hope to publish articles covering such companies approximately 3 times per week, with extensive quarterly follow-ups and constant updates.I manage a concentrated portfolio targeted at avoiding losers and maximizing exposure to big winners. This means that often I'll rate great companies at a 'Hold' because their growth opportunity is below my threshold, or their d ...
Equinor: Share Price Pullback Makes It A High Dividend-Yielding Investment Opportunity
Seeking Alpha· 2025-12-25 13:32
欧洲天然气库存状况 - 欧洲天然气库存全年趋势低于五年平均水平 目前库存水平较五年平均水平低约10% [1] 相关公司交易活动 - 分析师已开始买入Equinor公司股票 [1]
Innovative Aerosystems: High Growth Projections For High Reward
Seeking Alpha· 2025-12-25 13:30
Innovative Aerosystems ( ISSC ) is setting its sights on substantial growth over the coming years through organic reinvestment in advancing cockpit automation and through acquisitions. With management aiming to achieve $250 million in net revenue with an adjusted EBITDA margin ofMonte Independent Investment Research: Michael Del Monte is a buy-side equity analyst with expertise in the technology, energy, industrials, and materials sectors. Prior to working in the investment management industry, Michael spen ...
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts
Seeking Alpha· 2025-12-25 13:30
Here at the Lab, we generally do not cover late-stage clinical oncology companies. Still, this time, ArriVent BioPharma ( AVBP ) warrants an exception due to Firmonertinib’s near-term catalysts (Fig. 1) and the Chinese asset’s origin profile. This remains aBuy-side hedge professionals conducting fundamental, income oriented, long term analysis across sectors globally in developed markets. Please shoot us a message or leave a comment to discuss ideas.DISCLOSURE: All of our articles are a matter of opinion, i ...